GGrantIndex
← Leaderboards

Fei Wang

Weill Medical Coll Of Cornell Univ

$8,043,905
Attributed
$21,829,250
Total exposure
9
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.9M · FY202025
$10M$7.5M$5M$2.5M$0
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,829,250 · 9

By mechanism

R01$14,951,885 · 6
RF1$5,178,107 · 2
OT2$1,699,258 · 1

Top collaborators

Most similar at Weill Medical Coll Of Cornell Univ

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Alzheimer&Apos

Research focus

Alzheimer&AposMachine LearningCohortSuccessS DiseaseAmericanElectronic Health RecordMethodologyUnited StatesAlgorithmsAffectCharacteristicsS Disease PatientNatural Language ProcessingPharmaceutical PreparationsSignal TransductionDisease ProgressionS Disease RiskClinical TrialsClinical ResearchMedicineData SourcesData ScienceCause Of Death

Grant awards (23)

HF-ETIOLOGY: Heart Failure Endotypes from Ethical, Multi-Modal AI driven and Molecular/Phenotypic Data Integration Enabled Discovery$1,699,258
OT2 · FY2025 · OD
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s Disease$781,379
R01 · FY2025 · AG
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI$754,110
R01 · FY2025 · AG · contact PI
Disparities of Alzheimer's disease progression in sexual and gender minorities$750,304
R01 · FY2025 · AG
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge$740,268
R01 · FY2025 · AG · contact PI
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers$733,178
R01 · FY2025 · AG
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s Disease$809,747
R01 · FY2024 · AG
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI$790,377
R01 · FY2024 · AG · contact PI
Disparities of Alzheimer's disease progression in sexual and gender minorities$781,383
R01 · FY2024 · AG
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge$766,946
R01 · FY2024 · AG · contact PI
Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of Health$2,561,480
RF1 · FY2023 · AG
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI$820,172
R01 · FY2023 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s Disease$817,408
R01 · FY2023 · AG
Disparities of Alzheimer's disease progression in sexual and gender minorities$809,623
R01 · FY2023 · AG
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge$775,212
R01 · FY2023 · AG · contact PI
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data Fusion$750,817
R01 · FY2023 · MH
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers$330,271
RF1 · FY2023 · AG
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s Disease$831,528
R01 · FY2022 · AG
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge$807,473
R01 · FY2022 · AG · contact PI
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data Fusion$778,997
R01 · FY2022 · MH
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers$2,286,356
RF1 · FY2021 · AG
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data Fusion$798,717
R01 · FY2021 · MH
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data Fusion$854,246
R01 · FY2020 · MH